EANS-News: Epigenomics AG announces non-exclusive licensing agreement for Septin9 with Companion Dx Reference Lab

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Licensing Agreements/Company Information/molecular diagnostic

Berlin, Germany, and Seattle, WA, U.S.A., June 19, 2012 (euro adhoc)
- Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American
cancer molecular diagnostics company, announced today that it signed
a non-exclusive licensing agreement for its proprietary DNA
methylation biomarker Septin9 with Companion Dx Reference Lab
("Companion Dx"), an emerging leader in pharmacogenomic testing and
cancer companion diagnostics. Under the terms of the agreement,
Companion Dx has obtained rights to establish and commercialize a
blood-based, laboratory-developed test (LDT) using methylated Septin9
as biomarker for the detection of colorectal cancer. Epigenomics is
entitled to double digit royalties on sales.

"The addition of Septin9 to our offering of cancer related products
will allowusto more effectively serve theTexas cancertesting market.
Colorectal cancer is the second leading cause of cancer-related
deaths in the U.S., and we believe that thebloodbased method to
detect colorectal cancer in the currently non-compliantpatient
population will improve participation in screening and therefore save
more lives in Texas", said Steve Blum, CEO of Companion Dx.

"Based on thegrowing uptake of the Septin9 assay through our LDT
licensees, we are excited to add regionally focused Companion Dxlab
to thelist ofour partnersaswe recognize their ability to reach
incrementalsub-populations who should be but are not currently
screened according to guidelines", said Noel Doheny, Chief Executive
Officer of Epigenomics' US subsidiary. "Companion Dx shares our
objective of providing tests that will help physicians to improve the
health outcomes for patients through accurate detection of colorectal
cancer and to potentiallydecrease the risingcosts associated with
colorectal cancer in the U.S. With today's licensing agreement, we
continue to execute on our commercialization strategy, well ahead of
the launch of a proprietary diagnostic product approved by the FDA",
explained Mr. Doheny.

The agreement with Companion Dx complements Epigenomics' LDT
agreements with Quest Diagnostics, ARUP Laboratories and Warnex
Medical Laboratories in North America. Furthermore, Abbott Molecular
has worldwide, non-exclusive license to develop and to commercialize
IVD test kit products while Qiagen and Sysmex have acquired options
to do so.

- Ends -

Contact Epigenomics AG

Antje Zeise
Manager IR | PR
Epigenomics AG
Tel +49 (0) 30 24345 368
ir@epigenomics.com
www.epigenomics.com

About Epigenomics

Epigenomics (www.epigenomics.com) is a molecular diagnostics company
developing and commercializing a pipeline of proprietary products for
cancer. The Company's products enable doctors to diagnose cancer
earlier and more accurately, leading to improved outcomes for
patients. Epigenomics' lead product, Epi proColon®, is a blood-based
test for the early detection of colorectal cancer, which is currently
marketed in Europe and is in development for the U.S.A. The Company's
technology and products have been validated through multiple
partnerships with leading global diagnostic companies including
Abbott, QIAGEN, Sysmex, and Quest Diagnostics. Epigenomics is an
international company with operations in Europe and the U.S.A.

About Companion Dx

Companion Dx Reference Lab, LLC is a molecular diagnostic reference
laboratory and innovative leader in personalized medicine enabling
physicians to tailor medications to their patients based on the
individual genetic characteristics. Companion Dx offers a
comprehensive list of cutting-edge pharmacogenomic (genetic drug
sensitivity) assays and cancer companion diagnostics using
state-of-the-art technologies. The company is located in the
Biotechnology Commercialization Center at the University of Texas
Health Science Center in the Houston Texas Medical Center, the
world's largest medical center. For more information, please visit
companiondxlab.com.

Epigenomics legal disclaimer

This communication expressly or implicitly contains certain
forward-looking statements concerning Epigenomics AG and its
business. Such statements involve certain known and unknown risks,
uncertainties and other factors which could cause the actual results,
financial condition, performance or achievements of Epigenomics AG to
be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements.
Epigenomics AG is providing this communication as of this date and
does not undertake to update any forward-looking statements contained
herein as a result of new information, future events or otherwise.

The information contained in this communication does not constitute
nor imply an offer to sell or transfer any product, and no product
based on this technology is currently available for sale by
Epigenomics in the United States or Canada. The analytical and
clinical performance characteristics of any Epigenomics product based
on this technology which may be sold at some future time in the U.S.
have not been established.

Further inquiry note:
Antje Zeise | CIRO
Manager IR/PR
Epigenomics AG
Tel: +49 30 24345 386
antje.zeise@epigenomics.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

company: Epigenomics AG
Kleine Präsidentenstraße 1
D-10178 Berlin
phone: +49 30 24345-0
FAX: +49 30 24345-555
mail: ir@epigenomics.com
WWW: http://www.epigenomics.com
sector: Biotechnology
ISIN: DE000A1K0516
indexes: Prime All Share, Technology All Share
stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart,
regulated dealing/prime standard: Frankfurt
language: English